In the following study we used in vitro experiments to analyse the allogenic T-cell-transfer as an immunotherapeutic approach to tumor treatment. Using FACS-analysis we tested the binding ability of seven different tumor and tissue specific peptides to HLA-A2 positive T2 cells. The results were compared against two prognosis algorithms (SYFPEITHI- and Bimas-Score). The comparison showed that the measured peptide binding ability to T2-cells correlated strongly with the SYFPEITHI-Score and less with the Bimas-Score. We recorded a stimulation kinetic of allogenic T-cells activated with different pulsed T2-cells, which showed neither a peptide specificity nor a HLA- haplotype specificity. The maximum of stimulation was reached after five to six days. Two depletion methods (IFN-γ-Secretion-Assay and AICDDepletion) were tested for the selection of peptide specific T-cells. By comparison, the higher depletion effect was reached through AICD-Depletion. The granzyme B-ELISpot was applied to test the functionality of depleted T-cells. However, a peptide specificity could not be detected. This could also be extremely problematic because of the distinctive alloreactivity in using allogenic T-cells. In summary, of the seven peptides analysed, we found evidence of peptide specific activation for the tumor specific peptide 6 (EWS/FLI-1) and the tissue specific peptide 2 (CD79B).